134 related articles for article (PubMed ID: 35772575)
1. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy.
Ratnayake G; Reinwald S; Edwards J; Wong N; Yu D; Ward R; Smith R; Haydon A; Au PM; van Zelm MC; Senthi S
Radiother Oncol; 2022 Aug; 173():299-305. PubMed ID: 35772575
[TBL] [Abstract][Full Text] [Related]
2. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract][Full Text] [Related]
3. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
6. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
7. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
9. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
[TBL] [Abstract][Full Text] [Related]
11. Single-cell analysis of peripheral CD8
Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
[TBL] [Abstract][Full Text] [Related]
12. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial.
Ratnayake G; Reinwald S; Shackleton M; Moore M; Voskoboynik M; Ruben J; van Zelm MC; Yu D; Ward R; Smith R; Haydon A; Senthi S
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):150-156. PubMed ID: 32450331
[TBL] [Abstract][Full Text] [Related]
14. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Tang C; Welsh JW; de Groot P; Massarelli E; Chang JY; Hess KR; Basu S; Curran MA; Cabanillas ME; Subbiah V; Fu S; Tsimberidou AM; Karp D; Gomez DR; Diab A; Komaki R; Heymach JV; Sharma P; Naing A; Hong DS
Clin Cancer Res; 2017 Mar; 23(6):1388-1396. PubMed ID: 27649551
[No Abstract] [Full Text] [Related]
17. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
Edwards J; Tasker A; Pires da Silva I; Quek C; Batten M; Ferguson A; Allen R; Allanson B; Saw RPM; Thompson JF; Menzies AM; Palendira U; Wilmott JS; Long GV; Scolyer RA
Clin Cancer Res; 2019 Jun; 25(11):3247-3258. PubMed ID: 30777877
[TBL] [Abstract][Full Text] [Related]
18. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.
De Wolf K; Kruse V; Sundahl N; van Gele M; Chevolet I; Speeckaert R; Brochez L; Ost P
J Transl Med; 2017 Jan; 15(1):21. PubMed ID: 28137295
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]